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CObjective:We previously reported no difference in morbidity or mortality in a cohort of infants undergoing stage
1 and 2 reconstructions for hypoplastic left heart syndromewith either a modified Blalock–Taussig shunt or a right
ventricular to pulmonary artery conduit. This article compares the hemodynamics and perioperative course at the
time of the Fontan completion and reports longer-term survival for this cohort.
Methods:We retrospectively reviewed the hospital records of all patients who underwent stage 1 reconstruction
between January 2002 and May 2005 and subsequent surgical procedures, as well as cross-sectional analysis of
hospital survivors.
Results:A total of 176 patients with hypoplastic left heart syndrome or a variant underwent stage 1 reconstruction
with either modified Blalock–Taussig shunt (n ¼ 114) or right ventricular to pulmonary artery conduit (n ¼ 62).
Shunt selection was at the discretion of the surgeon. The median duration of follow-up was 58 months (range
1–87 months). By Kaplan–Meier analysis, shunt type did not influence survival or freedom from transplant at
5 years (right ventricular to pulmonary artery conduit 61%; 95% confidence limit, 47–72 vs modified
Blalock–Taussig shunt 70%; 95% confidence limit, 60–77; P ¼ .55). A total of 107 patients underwent Fontan
(69 modified Blalock–Taussig shunts and 38 right ventricular to pulmonary artery conduits) with 98% (105/107)
early survival. Patients with a right ventricular to pulmonary artery conduit shunt pre-Fontan had higher pulmo-
nary artery (13 8 mmHg vs 11 3 mmHg, P¼ .026) and common atrial (8 2.3 mmHg vs 6.8 2.7 mmHg,
P ¼ .039) pressures. By echocardiography evaluation, there was more qualitative moderate to severe ventricular
dysfunction (right ventricular to pulmonary artery conduit 31% [12/36] vs modified Blalock–Taussig shunt 17%
[11/67], P ¼ .05) and moderate to severe atrioventricular valve regurgitation (right ventricular to pulmonary ar-
tery conduit 40% [14/35] vs modified Blalock–Taussig shunt 16% [11/67], P ¼ .01) in the right ventricular to
pulmonary artery conduit group. Use of diuretic therapy, angiotensin-converting enzyme inhibition, reflux med-
ications, and tube feedings were not different between groups. Overall, 5 patients underwent heart transplantation
(right ventricular to pulmonary artery conduit 4 vs modified Blalock–Taussig shunt 1, P ¼ .1) before Fontan.
There was no difference in age or weight at Fontan, bypass time, intensive care unit or hospital length of stay,
postoperative pleural effusions, or need for reoperation between groups.
Conclusions: Interim analyses continue to suggest there is no survival advantage of one shunt type compared
with the other. Longer-term follow-up of a randomized patient population remains of utmost importance.
(J Thorac Cardiovasc Surg 2010;140:537-44)In the absence of transplantation, hypoplastic left heart
syndrome (HLHS) and variants are palliated with a staged
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The Journal of Thoracic and Caflow can be supplied via a modified Blalock–Taussig shunt
(mBTS) or a right ventricle to pulmonary artery (RV-PA)
conduit. A contemporary comparison of the immediate
hemodynamics after S1R with both shunt types in a non-
randomized study did not demonstrate benefit of one shunt
type versus the other.1 Longer-term follow-up studies
through stage 2 reconstruction (S2R) also have not demon-
strated advantage of one shunt type versus the other.2,3
To date, there are few studies that define the morbidity and
mortality at Fontan using both shunt types. A study using
historical controls4 and a single study with contemporary
controls5 have not demonstrated significant advantage to
one shunt type at the time of Fontan completion. We there-
fore undertook the current study to better define the out-
comes at the time of Fontan completion and longer-termrdiovascular Surgery c Volume 140, Number 3 537
Abbreviations and Acronyms
AVVR ¼ atrioventricular valve regurgitation
HLHS ¼ hypoplastic left heart syndrome
mBTS ¼ modified Blalock–Taussig shunt
RV-PA ¼ right ventricle to pulmonary artery
S1R ¼ stage 1 reconstruction
S2R ¼ stage 2 reconstruction
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Our study objectives include the difference between the 2
shunt groups with regard to (1) preoperative hemodynamics
and patient characteristics, (2) Fontan morbidity and mortal-
ity, and (3) interim mortality of the entire study cohort.MATERIALS AND METHODS
This study was a cross-sectional case series including all patients who
underwent an S1R for HLHS or variants at The Children’s Hospital of
Philadelphia between January 1, 2002, andMay 1, 2005 (n¼ 176), with par-
ticular attention paid to S2R hospital survivors (n ¼ 119). This was a con-
sent-waived study approved by The Children’s Hospital of Philadelphia
Institutional Review Board. Sources of information included the hospital
medical records, cardiac center and cardiac intensive care databases, records
and reports provided by referring cardiologists, and pertinent information
obtained from the parents on interview. Patient data were collected through
April 16, 2009.
All patients were born with HLHS or variants with a single ventricle and
obstruction to systemic blood flow. Anatomic diagnoses were divided into
(1) usual HLHS with mitral stenosis or atresia; (2) malaligned atrioventric-
ular canal defect with a single right ventricle; (3) ventricular septal defect or
double-outlet right ventricle with mitral stenosis or atresia; (4) single left
ventricle with systemic outflow obstruction, such as double-inlet left ventri-
cle with transposition of the great arteries; and (5) other, including truncus
arteriosus with single ventricle.
We reviewed the most recent clinic visit or admission note for use of di-
goxin, diuretic therapy, angiotensin-converting enzyme inhibitor agents,
and anti-reflux medications. We recorded data on need for supplemental
feeding via nasogastric or gastrostomy tubes and need for occupational,
speech, or physical therapy. Reported developmental delay was recorded.
We reviewed the most recent echocardiographic report before Fontan
completion for the study patients. Echocardiographers were not blinded
as to the type of initial shunt type chosen for pulmonary blood. Reported
qualitative assessments of systolic ventricular function, atrioventricular
valve regurgitation (AVVR), and neoaortic valve regurgitation were re-
corded. Systolic ventricular function was documented as normal, mild,
moderate, or severely depressed. AVVR and neoaortic valve regurgitation
were documented as none, mild, moderate, or severe in nature.
Oximetry and hemodynamic data obtained at cardiac catheterization
with conscious sedation or general anesthesia before Fontan completion
were collected. Measured data included hemoglobin concentration, venous
and arterial saturations, common atrial pressure, pulmonary artery pressure,
and single ventricle end-diastolic pressure. If magnetic resonance imaging
was used in place of or in addition to cardiac catheterization before Fontan
completion, this was recorded.
The operative techniques for S1R and S2R have been described.1,2 As
previously described, initial shunt type was at the discretion of the
surgeon and included the use of the mBTS for all patients with single left
ventricle and a preference for the RV-PA conduit in patients with aortic atre-
sia.1 At the time of S2R, no patient was left with antegrade flow. Type of538 The Journal of Thoracic and Cardiovascular SurgFontan (lateral tunnel or extracardiac) procedure was at the discretion of
the surgeon. Age and size at Fontan and comparative operative data, includ-
ing total support time, aortic crossclamp time, and deep hypothermic circu-
latory arrest time, were recorded. Postoperative data, including length of
intubation, incidence of reintubation, and cardiac intensive care unit and
hospital lengths of stay, were also recorded. Need for extracorporeal mem-
brane oxygenation, reoperation, or cardiac catheterization before discharge
or listing for transplantation was documented. Other perioperative morbid
events, including placement of chest tubes and wound infections, were
documented. The incidence of rehospitalization was obtained to assess
the postdischarge morbidity. For rehospitalization, the indications for ad-
mission, length of stay, invasive procedures performed, and outcome
were ascertained from the medical records or the parents directly.
Data are presented as medians (ranges) or means ( standard deviation)
for continuous variables and as a count and percentage for dichotomous var-
iables. Continuous variables were compared by using the Mann–Whitney
test and Student t test. Fisher’s exact test and chi-square analyses were
used for dichotomous and categoric variables. The Kaplan–Meier method
was used to generate survival curves beginning at birth using a composite
end point of death or transplantation that occurred up to the time of final
data collection. Comparison between survival curves by shunt type was
performed using the log-rank method. Multivariate modeling using Cox
proportional hazards regression was used to adjust for differences in base-
line characteristics between shunt types to determine the association
between shunt type and the composite outcome. Variables were included
in the model for adjustment if the significant difference between shunt types
was P less than .1. All data were analyzed by using STATA 9.2 software
(STATA Corp, College Station, Tex).RESULTS
Patient Population
The study population consisted of 176 patients who un-
derwent S1R for HLHS or variants with a single ventricle
and systemic outflow obstruction. Anatomic subtype has
been reported.1 Cardiac anatomy and previously reported
risk factors stratified by shunt type can be found in Table
1. In addition, since the introduction of the RV-PA conduit
in early 2002, there has been consistent use of both shunts
throughout the study period (Figure 1). Fluctuations over
time may reflect the patient population (specific anatomy),
surgeon, or recent successes or failures of a particular shunt
type. The RV-PA conduit was preferred for patients with
aortic atresia or an aberrant right subclavian artery, and the
mBTS was preferred for patients with a single LV. Patients
were relatively evenly distributed between shunt types with
respect to previously reported risk factors (exclusive of car-
diac anatomy) with the exception of noncardiac anomalies
(Table 1).
Follow-up data are complete through April 16, 2009.
Incomplete data are available for 6 patients in the RV-PA
conduit group who underwent Fontan completion at other
institutions. No patient has been lost to follow-up. An
mBTS was placed in 114 patients, and an RV-PA conduit
was placed in 62 patients.1 The outcomes through S2R
have been described.2 At the time of S2R analysis, 78 of
80 patients palliated with mBTS had undergone S2R, with
2 patients awaiting further palliation to Glenn physiology.
Similarly, 46 of 47 patients palliated with RV-PA conduitery c September 2010
TABLE 1. Baseline cardiac anatomy and previously reported risk
factors stratified by shunt type before stage 1 reconstruction
mBTS (n ¼ 114) RV-PA (n ¼ 62) P
Cardiac anatomy
HLHS 66 (57.9%) 55 (88.7%) <.001
Unbalanced AVC 11 (9.7%) 4 (6.5%) .58
VSD with MS/MA 18 (15.8%) 2 (3.2%) .012
Single LV 17 (14.9%) 0 (0%) .001
Other 2 (1.8%) 1 (1.6%) 1
Aortic atresia 35 (30.5%) 43 (69.4%) <.001
Previously reported
risk factors
Birth weight<2.5 kg 22 (19.3%) 14 (22.6%) .7
Noncardiac anomalies 7 (2.6%) 7 (11.3%) .035
Genetic syndrome 5 (4.4%) 3 (4.8%) 1
Associated cardiac
risk factors
15 (13.5%) 3 (4.9%) .08
Preoperative shock 9 (8%) 5 (8%) 1
AVC, Atrioventricular canal; VSD, ventricular septal defect; MS, mitral stenosis; MA,
mitral atresia. Shunt type ¼ RV-PA compared with mBTS baseline.
Other ¼ unbalance AVC with truncus arteriosus and interrupted aortic arch, superior
ventricles with AVC and transposition of the great arteries {S,D,L} with mitral steno-
sis. Additional cardiac risk factors were considered to be an intact atrial septum requir-
ing emergency intervention, moderate to severe AVVR, and severe ventricular
dysfunction at birth. Noncardiac anomalies included scimitar syndrome, gastroschisis,
duodenal atresia, and tracheoesophageal fistula.
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tion. Of the 116 S2R survivors, 107 have undergone Fontan
completion (mBTS 69/72; RV-PA 38/40; P ¼ .79)
(Figure 2). Four other procedures have been performed:
One patient in the mBTS cohort underwent conversion to
2-ventricle palliative repair, and 2 patients in the RV-PA
conduit cohort underwent transplantation. Five patients are
awaiting Fontan completion: 3 in the mBTS group and 2FIGURE 1. Distribution of shunt types over time (n ¼ total stage I reconstructi
months. mBTS (light gray bars) and RV-PA conduit (dark gray bars). mBTS,M
The Journal of Thoracic and Cain the RV-PA conduit group. Two of the 3 patients in the
mBTS cohort remain palliated with shunt physiology. Inter-
stage mortality, defined as death after hospital discharge
from S2R and before Fontan completion, was not signifi-
cantly different between shunt types (mBTS 6.3% [5/80];
RV-PA 6.4% [3/47]; P ¼ .7).Preoperative Morbidity
We compared age, patient size, medication use, and need
for supplemental feeding at the time of Fontan completion.
There was no difference in the age of patients between shunt
types (mBTS 2.7 years [range, 1.5–4.4 years]; RV-PA 2.9
years [range, 1.9–3.9 years], P ¼ .4). In addition, patient
size as measured by weight and body surface area at the
time of surgery was not different between shunt types
(Table 2). The use of diuretic therapy, angiotensin-
converting enzyme inhibitors, reflux medications, and tube
feedings was not different between groups (Table 2). The
use of digoxin was significantly more frequent in patients
in the RV-PA group (mBTS 234% [17/72], RV-PA 43%
[16/37]; P ¼ .04). A total of 32 patients were receiving oc-
cupational/physical or speech therapy at the time of Fontan
completion. There was no difference in shunt type and need
for therapy or diagnosis of developmental delay (mBTS
28% [20/72], RV-PA 40% [15/38]; P ¼ .13).Preoperative Echocardiographic Data
The RV-PA cohort had significantly more moderate to se-
vere qualitative ventricular systolic dysfunction in the RV-
PA cohort (mBTS 16% [11/67]; RV-PA 31% [11/36],
P ¼ .05). There was also more moderate to severe AVVR
in the RV-PA cohort (mBTS 16% [11/67]; RV-PA 40%on during the time block). All time blocks are 6 months, except the last is 5
odified Blalock–Taussig shunt; RV-PA, right ventricle to pulmonary artery.
rdiovascular Surgery c Volume 140, Number 3 539
FIGURE 2. Outcomes of 176 patients who underwent S1R between January 1, 2002, and May 1, 2005. mBTS, Modified Blalock–Taussig shunt; RV-PA,
right ventricle to pulmonary artery; ISD, interstage death; OHT, orthotopic heart transplant.
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different between shunt types.
Preoperative Cardiac Catheterization Data
Eighty-one patients underwent preoperative cardiac cath-
eterization (mBTS 77% [53/69], RV-PA 74% [28/38],
P ¼ .9). Ten patients underwent magnetic resonance imag-
ing evaluation, and the remaining patients were assessed
only with echocardiography before Fontan. There was no
difference in the mixed venous saturation between shunt
types (mBTS 63% [range 48%–77%]; RV-PA 60% [range
45%–74%], P¼ .7). Common atrial pressure (mBTS 7 mm
Hg [range 3–13 mm Hg], RV-PA 8 mmHg [range 4–15 mm
Hg], P ¼ .04) and mean pulmonary artery pressure (mBTS
11 mm Hg [range 6–24 mm Hg]; RV-PA 13 mm Hg [range
8–24 mm Hg], P¼ .03) were significantly higher in patients
with RV-PA conduits at the pre-Fontan catheterization.
There was a trend toward higher single ventricle end-
diastolic pressure (mBTS 6 mm Hg [range 4–14 mm Hg];
RV-PA 8 mm Hg [range 5–15 mm Hg], P ¼ .06) in patients
with RV-PA conduits.
Fontan Operative Data and Morbidity
The Fontan completion consisted of a fenestrated lateral
tunnel Fontan or a fenestrated extracardiac conduit. ThereTABLE 2. Preoperative patient characteristics
mBTS RV-PA conduit P value
Age (y) 2.7 (1.5–4.4) 2.9 (1.9–3.9) .4
Weight (kg) 13 (9.2–17.6) 13.5 (11–17.6) .3
BSA (m2) 0.55 (0.41–0.7) 0.55 (0.39–0.71) .7
Diuretic use 26/69 14/35 .5
ACEI use 45/69 25/35 .3
Digoxin use 17/72 16/37 .04
Reflux medication use 16/69 7/35 .5
NG or G-tube feeding 8/69 6/35 .3
mBTS, Modified Blalock–Taussig shunt; RV-PA, right ventricle to pulmonary artery;
BSA, body surface area; ACEI, angiotensin-converting enzyme inhibitor;NG, nasogas-
tric;G, gastric. Data presented as median with range. P values calculated usingMann–
Whitney test.
540 The Journal of Thoracic and Cardiovascular Surgwas no difference in total support time, aortic crossclamp
time, or circulatory arrest time between shunt types
(Table 3). The median total support time was 66 (range
52–195) minutes for the mBTS group and 64 (range
50–134) minutes for the RV-PA conduit group (P ¼ .19).
Five patients underwent atrioventricular valvuloplasty at
the time of Fontan (mBTS 2/69; RV-PA 3/38; P ¼ .5).
There was no difference in the time to initial extubation,
with the majority of the patients in both groups being extu-
bated on arrival into the cardiac intensive care unit after Fon-
tan completion. One patient in the RV-PA conduit group
required reintubation for respiratory failure and eventual tra-
cheostomy for subglottic stenosis. Two patients in the mBTS
group required prolonged intubation (3 and 6 days, respec-
tively) for low output state and eventual Fontan takedown
related to Fontan baffle obstruction. Nine patients underwent
cardiac catheterization during the same admission, after
Fontan procedure (mBTS 7/69, RV-PA 2/38; P ¼ .6); inter-
ventions including relief of arch obstruction (n ¼ 2) and
stent placement in the left pulmonary artery (n ¼ 1) were
performed. Other measures of morbidity included both hos-
pital and cardiac intensive care unit lengths of stay. Neither
measure was significantly different between groups, with
a median length of hospital stay for both groups of 8 days
(mBTS range 4–40 days, RV-PA 2–73 days; P ¼ .6) and
a median length of intensive care unit stay of 7 days
(mBTS range 2–40 days, RV-PA 1–73 days; P ¼ .3). Chest
tubes were placed for pleural effusions in 21 of 69 patients in
the mBTS group and 13 of 38 patients in the RV-PA conduit
group (P ¼ .6). Four patients (mBTS 3/69, RV-PA 1/38;
P ¼ .9) required mediastinal incision and drainage.
There was an 18% rehospitalization rate within 30 days
after initial discharge after Fontan completion (mBTS
15% [10/69]; RV-PA 16% [6/38]; P ¼ .9). Three patients
with initial mBTS and 1 patient with RV-PA conduit had
more than 1 readmission within 30 days of discharge, result-
ing in a higher total rehospitalization rate for the entire
cohort than for 1 single shunt type. Median length of stayery c September 2010
TABLE 3. Operative times at Fontan by shunt type
mBTS (n ¼ 62) RV-PA conduit (n ¼ 31)
Total support
time (min)
66 (52–189) 64 (50–134) P ¼ .07
Aortic crossclamp
time (min)
27 (0–91) 25 (14–65) P ¼ .12
DHCA (min) 25 (0–82) 25 (14–41) P ¼ .08
mBTS, Modified Blalock–Taussig shunt; RV-PA, right ventricle to pulmonary artery
conduit; DHCA, deep hypothermic circulatory arrest. Data presented as median with
range. P values calculated using Mann–Whitney test.
TABLE 4. Cox proportional hazard regression models for death or
transplant: Entire cohort
Risk factor Hazard ratio 95% CL P value
Shunt type 1 0.54–1.93 .96
Single left ventricle 0.30 0.07–1.32 .11
Unbalanced AVC 1.43 0.6–3.42 .42
VSD with MS/MA 0.79 0.32–1.98 .62
Other 0.42 0.054–5.26 .41
Aortic atresia 0.88 0.48–1.63 .69
Associated cardiac
risk factors
2.5 1.19–5.26 .02
Significant congenital
anomalies
4.5 1.96–10.21 <.001
Defined genetic syndrome 0.29 0.04–2.17 .23
Birth weight<2.5 kg 3.19 1.8–5.8 <.0001
Shock at birth 1.72 0.76–3.92 .19
AVC, Atrioventricular canal; CL, confidence limit; VSD, ventricular septal defect;MS,
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(mBTS median 7 days [range 2–36 days], RV-PA median
6.5 days [range 1–25 days], P ¼ .4). The reason for admis-
sion for all patients was pleural effusion, with 1 patient also
having a superficial wound infection.mitral stenosis; MA, mitral atresia. Shunt type is RV-PA compared with mBTS base-
line. Other ¼ unbalanced AVC with truncus arteriosus and interrupted aortic arch, su-
perior ventricles with AVC and transposition of the great arteries {S,D,L} with mitral
stenosis. Additional cardiac risk factors were considered to be an intact atrial septum
requiring emergency intervention, moderate to severe AVVR, and severe ventricular
dysfunction at birth. Noncardiac anomalies included scimitar syndrome, gastroschisis,
duodenal atresia, and tracheoesophageal fistula.Mortality and Follow-up
There was 98% surgical survival for those patients under-
going Fontan completion. The 2 surgical deaths were in the
mBTS group. One patient died of overwhelming gram-
negative rod sepsis with uncontrollable hemorrhage. The
second patient had a sudden cardiac arrest requiring extra-
corporeal membrane oxygenation cannulation with subse-
quent withdrawal of support secondary to embolic
complications of heparin-induced thrombocytopenia.
The median duration of follow-up was 58 months (range
1–87 months). By Kaplan–Meier analysis, shunt type did
not influence survival or freedom from transplant at 5 years
(mBTS 70%; 95% confidence limit, 60–77, vs RV-PA
61%, 95% confidence limit, 47–72; P ¼ .55; Figure 3).
There have been no deaths or transplants in either group after
Fontan completion and hospital discharge through the
current follow-up.
Further analysis using Cox proportional hazards regres-
sion was performed to adjust for differences in baseline
characteristics between the 2 groups (Table 4). VariablesFIGURE 3. Kaplan–Meier freedom from death or transplant by shunt type.
Start point is birth with follow-up to April 16, 2009.
The Journal of Thoracic and Caadded into the model included cardiac diagnosis, additional
cardiac risk factors, significant noncardiac anomalies, and
aortic atresia (Table 1). By adjusting for these differences
in baseline characteristics, there was no significant associa-
tion between shunt type and death or transplant (hazard ratio
1.0; 95% confidence interval, 0.54–1.93). By restricting the
model to only those patients with HLHS, there was still no
significant association between shunt type and outcome
(hazard ratio 1.17; 95% confidence interval, 0.54–2.44).DISCUSSION
This most recent review of this contemporary cohort of
patients demonstrates several significant findings. There
was significantly more qualitative ventricular dysfunction
and AVVR in those patients who underwent RV-PA conduit
as part of the S1R. These patients also had significantly
higher common atrial and mean pulmonary artery pressures
at the time of pre-Fontan catheterization. However, despite
these significant differences, the ability to tolerate Fontan
completion was not different between shunt groups. In
addition, freedom from death or transplant was not different
between groups, with a median follow-up time of approxi-
mately 5 years. Multivariate analysis did not demonstrate
a protective effect of the anatomic subtype of single left
ventricle or of one shunt type over the other. As previously
reported, the presence of additional cardiac risk factors and
noncardiac congenital anomalies was highly predictive of
worse outcome.1 The pattern of interstage death and trans-
plantation at this point in follow-up seems to demonstrate
a trend toward early attrition in the group with mBTS and
late attrition in the RV-PA conduit group, which may berdiovascular Surgery c Volume 140, Number 3 541
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noted in the RV-PA group.
Multiple factors have resulted in improved survival
among infants born with functional single-ventricle lesions.
These factors include surgical modifications, improved sur-
gical technique, modifications to preoperative and postoper-
ative care, and a better understanding of the cardiac
physiology of a patients with single-ventricle lesions under-
going surgical reconstruction.6-11 The most recent
modification is the use of an RV-PA conduit. This technique
was first described by Norwood and colleagues12 in the early
1980s but was abandoned in favor of a systemic to pulmo-
nary shunt. In recent years, multiple centers have reported
improved surgical survival with the use of this conduit
when compared with historical controls through the first in-
terstage period.13,14 Several large centers have published
contemporary series that have not demonstrated the benefit
of either shunt strategy through S1R and S2R.1-3
Few reports are available detailing intermediate and
longer-term outcomes after the use of RV-PA conduit at
S1R through Fontan completion. Januszewska and col-
leagues4 reported no difference in mortality, ventricular
function, arrhythmia, or length of stay in a consecutive series
of 50 patients with HLHS at the time of Fontan completion.
In addition, a more recent report of a series of 80 patients
who contemporaneously underwent S1R with either
mBTS or RV-PA conduit did not demonstrate a statistically
significant difference in outcome between shunt types.5 We
report our single-institution experience with Fontan comple-
tion and overall survival in a cohort of patients who under-
went S1R with either an mBTS or RV-PA conduit in the
same era with a median follow-up of 4 years.
Kaplan–Meier 5-year survival for the entire series cohort
is 68% (95% confidence limit, 58–75). A total of 107 pa-
tients underwent Fontan completion with 98% early sur-
vival. As demonstrated by Kaplan–Meier analysis, shunt
type did not influence survival or freedom from transplant
at 5 years (Figure 3). Although a larger number of patients
with RV-PA conduit underwent transplantation, this was
not statistically significant. All patients received transplants
as a result of severe ventricular dysfunction. Survival in our
cohort is similar to that reported in both historically con-
trolled and contemporary series of Fontan completion using
both shunt types.5,15 This early survival is also similar to that
previously reported in large, single institutional reviews of
Fontan outcomes after an initial Norwood procedure with
mBTS.16,17
Qualitative ventricular dysfunction was worse in those pa-
tients palliated initially with RV-PA conduit in comparison
with mBTS with nearly twice as many patients in the
RV-PA conduit group having an assessment of moderate
to severe ventricular dysfunction at the time of preoperative
Fontan evaluation. This association remained as strong at the
time of Fontan completion as it was at the time of S2R. In the542 The Journal of Thoracic and Cardiovascular Surginterim period, 3 patients with an RV-PA conduit and signif-
icant ventricular dysfunction underwent transplantation. It
remains unclear whether the ventriculotomy of the RV-PA
conduit is the cause of the impaired systolic ventricular per-
formance over time. These findings are in contrast with those
published by Boston Children’s Hospital, which reported
a trend toward improved outcome with the use of the RV-
PA conduit.5 In addition, although AVVR was significantly
worse at the time of Fontan completion in those patients with
a previous RV-PA conduit, it did not result in an inability to
undergo successful Fontan surgery. Marginally higher but
statistically significant, mean pulmonary artery pressure
and filling pressure at the time of the pre-Fontan cardiac cath-
eterization in those patients with a previous RV-PA conduit
did not limit Fontan suitability or successful completion.
Other preoperative patient characteristics, including need
for supplemental feeding, need for ancillary therapies, med-
ication use, age, and size at time of Fontan completion did
not differ between the 2 shunt types. Intraoperative times
were not different between groups, and the recovery from
surgery documented as time to extubation and length of
stay was not different between initial shunt types. Incidence
of pleural effusions, length of drainage, and need for reho-
spitalization for pleural effusions were similar between
groups. Pleural effusions did not seem to be related to pul-
monary artery architecture because only 1 patient required
an interventional intervention to relieve stenosis in the post-
operative Fontan period. There was no statistical association
between the presence of pleural effusions and the preopera-
tive pulmonary artery pressure or ventricular end-diastolic
pressure.
Study Limitations
This study is limited by its retrospective nature and the
biases inherent in this type of study design. This is a non-
randomized patient population, with possible uneven distri-
bution of unrecognized preoperative risk factors between
shunt groups. As previously stated, all patients with single
left ventricles were initially palliated with mBTS, and there
was a preference for the use of an RV-PA conduit in those
patients with aortic atresia. Although this was a contempo-
rary rather than historical comparison of shunt types, there
was uneven distribution of shunt types over time. Although
few patients were lost to follow-up, patients did not receive
the same preoperative evaluation, and as such some data
analysis may be biased. Echocardiographic data are what
were documented in the most recent report before Fontan
procedure. Images were not reviewed at the time of collec-
tion, which introduces the bias of multiple readers and
data interpretation. It is a recent study group, and important
late outcomes, such as arrhythmia, sudden death, and ven-
tricular dysfunction, might not have yet occurred. This study
might not be powered to evaluate small differences between
comparison groups.ery c September 2010
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The data of this contemporary cohort of patients do not
support the use of one shunt type over the other at the
time of the S1R as it relates to ability to proceed to Fontan
completion. Overall survival between shunt types remains
similar through Fontan completion; however, timing of
death and morbidity are different. There may be a survival
advantage early in the palliation period for patients with
RV-PA conduits, but this seems to diminish over time
with continued attrition with death and transplantation after
S2R. In addition, ventricular dysfunction and AVVR con-
tinue to be significant in those patients with RV-PA conduits
at the time of Fontan completion. This may contribute signif-
icantly to longer-term outcomes. As such, this limited study
group, with the inherent biases to this type of retrospective
study and the relatively short follow-up time period, empha-
sizes the need for longitudinal follow-up in a randomized,
controlled trial, such as the Single Ventricle Reconstruction
trial, which is ongoing at the current time.18
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Dr Christian Pizarro (Wilmington, Del). I congratulate Dr
Ballweg and colleagues on a timely study comparing the outcomes
of patients who underwent Fontan completion after receiving alter-
native sources of pulmonary blood flow at the time of their Nor-
wood procedure. While the pediatric cardiac surgical community
awaits the results of the Single Ventricle Reconstruction trial, these
data provide important information about the impact of each shunt
on the candidacy of these patients to undergo a Fontan procedure
and their operative results and midterm outcome.
The authors conclude that there is no evidence to support the use
of one shunt over the other; nevertheless, each group presented
a different pattern on the timing of death and morbidity. Although
there were more interstage deaths in the mBTS group, when using
a composite end point of death or transplantation, this difference is
neutralized by the fact that 3 patients in the RV-PA group under-
went transplantation after their second stage.
My first question, based on these different patterns of attrition, is
did you identify any specific subgroup of patients who would ben-
efit the most with one specific type of shunt?
Dr Ballweg.No, we did not. We haven’t looked back at the data
and teased out if patients with aortic atresia, those with mitral and
aortic atresia, or the group that some people have reported as higher
risk (ie, mitral stenosis and aortic atresia) would benefit from one
shunt type or the other at this point.
Dr Pizarro. Thank you, considering the difficulty related to the
objective evaluation of right ventricular function, the data pre-
sented show a substantially higher incidence of moderate to severe
right ventricular systolic dysfunction in the RV-PA shunt group,
a finding that has not consistently been reported in other series, par-
ticularly the one that you have mentioned. A review of our own ex-
perience, comparing the outcome of shunt types 3 years after the
Fontan, presented at the Society of Thoracic Surgeons last year,
did not detect any differences in systolic function; however, the in-
cidence and duration of pleural effusions showed a tight correlation
with a history of balloon intervention for recoarctation.
Have you had the opportunity to assess and compare the dia-
stolic properties of these ventricles, and have you observed a similar
phenomenon?
Dr Ballweg. I’ll answer the second part first. In regard to the data
you presented with coarctation and pleural effusions, there were in-
terventions on arch obstruction in these patients, but it was mainly
after Fontan. We have had some patients who also had pre-Fontan
arch obstruction that was relieved, and those patients did not have
increased duration or incidence of pleural effusion. Those data arerdiovascular Surgery c Volume 140, Number 3 543
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Dnot discussed in this article but will be presented in June at the
Western Thoracic Surgical Association meeting.
In regard to your first question, I’m not sure we have a good
method of evaluating diastolic dysfunction, quite honestly. I think
the data showing that the end-diastolic pressure and left atrial pres-
sure are increased are certainly markers that the diastolic function
of the ventricles may be worse for those with an RV-PA conduit
at stage 1.
Dr Pizarro. As longer follow-up is available, the issues of late
failure and need for transplantation becomematters of special inter-
est. TheMichigan group and others have shown that the outcome of
patients with tricuspid valve regurgitation after the Norwood is
closely related to the degree of ventricular dysfunction; therefore,
attempts to correct the tricuspid regurgitation should be undertaken
early. Given the fact that 40% of the patients in the RV-PA shunt
group had important tricuspid regurgitation, could you tell us
how these patients were managed? Did they undergo any attempt
at tricuspid valve repair before or at the time of Fontan, or have
you developed a protocol to address this important issue?
Dr Ballweg. In our previous discussion and publication at stage
2, we had 10 patients who had undergone tricuspid valvuloplasty, 4
were in the mBTS group and 6 were in the RV-PA conduit group.
Unfortunately, I don’t have the specific data on howmany tricus-
pid valvuloplasties were done at the time of the Fontan. I can tell
you of only one that I can recall. And in discussing this with other
people who are here at the meeting with me, it’s rare for us to inter-
vene on tricuspid regurgitation at the time of Fontan. It has to be
extremely severe; however, you want to define that, and certainly
it’s not the norm. So although we had a large percentage of patients
with tricuspid regurgitation by echo definition of multiple re-
viewers, we did not intervene.
As far as management, I think there is a certain camp that tends
to afterload reduce patients with AVVR more aggressively than
others. We do not have a standard protocol, but I think people
are aware that oftentimes afterload reduction may be helpful.
Dr Pizarro.We learned from your previous report on this cohort
of patients that those in the RV-PA group were younger and had
lower arterial saturations at stage 2. Did you observe any difference
in the degree of systemic to pulmonary collaterals present in these
patients before Fontan completion, and were there any differences
in the interventions undertaken?
Dr Ballweg. That wasn’t the objective of our study, and we
didn’t look for it. I don’t have those data to present today.
Dr Emile Bacha (Boston, Mass). I wonder if you’re not measur-
ing 2 different groups of patients. I may havemissed it in the presen-
tation. You probably know that tomorrow we’re presenting out of
Boston a similar series of patients with a bit longer follow-up, and
we found the exact opposite in terms of tricuspid regurgitation rates.544 The Journal of Thoracic and Cardiovascular SurgNow, you showed that approximately two thirds of your patients
had HLHS; the rest had single left ventricles (LVs) and so forth.
Those are patients in whom we would tend to perform mBTS.
Those are patients who tend to do much better in terms of AVVR
and ventricular function. So by comparing these 2 groups, I’m
assuming that you have more single LVs in the mBTS group.
I may be wrong, but that’s my assumption, and I wonder if you
would repeat this analysis with only patients with HLHS.
Dr Ballweg. There were 9 patients with single LVs, and they are
all in the mBTS group. Certainly we could exclude them and redo
the analysis just with HLHS and variants. The variants were the
more common things we see in such an unbalanced canal.
Dr Bacha. I would encourage you to do that because it would be
interesting to see what you find.
Dr Shunji Sano (Okayama City, Japan). The LV dysfunction
and tricuspid regurgitation are concerns for the RV-PA shunt.
But I think the LV dysfunction and tricuspid regurgitation can be
avoided mainly in 2 ways. One is the LV incision. We changed
the technique from excising the LV, the muscle, from the scissors
of knife to punch out the muscle, because it’s more accurate and
the damage to the LV is minimal, rather than the cutting knife
with scissors.
The second one is that the volume overload is also avoided by
putting a clip to the graft to control the saturation. When the oper-
ation is finished, we keep the saturation between 80% and 85%with
a clip, mostly to a 5-mm graft, because our patient population is
smaller than yours. So the volume overload could be controlled.
Then afterward, when the patients grow up, the cardiologists do
balloon dilate and remove the clip so that we can wait a little
more because the average body weight at Fontan is only 10 kg.
So there are 2 ways we can somehow control or manage or mini-
mize the LV dysfunction and tricuspid regurgitation.
What is your technique of LV incision? What size graft do you
use in an RV-PA shunt? When you finish the RV-PA shunt, how
much is the saturation, and can you try to control the saturation
to control the volume overload?
Dr Ballweg.We do not use the punch technique. So if you have
seen a change in ventricular dysfunction and AVVR, it may be
a better option. We do not do anything to control the pulmonary
blood flow through the Sano conduit at the time the operation is
completed. I believe the majority of our conduits are 5 mm as
well. Our saturations are generally in the mid to high 80s when
patients leave the operating room.
Dr Frank Hanley (Stanford, Calif). Was there any correlation
between the reduced right ventricular function by ejection fraction
determined by echocardiography and the right ventricular end-dia-
stolic pressure at the pre-Fontan catheterization?
Dr Ballweg. No, there was not.ery c September 2010
